Current Edition

ASH 2021

ASH: Novartis thinks it knows why Kymriah failed in earlier lymphoma but shifts focus to next-gen CAR-T meds

Kymriah’s shocking failure in earlier lymphoma treatment has raised doubts about the Novartis drug’s potency in light of impressive victories from rival CAR-Ts by Gilead …

Continue Reading →